ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased ...
ImmuPharma is a biopharmaceutical company that specialises in the usage and development of biopolymers, specifically peptides.
Our late-stage to preclinical pipeline is focused on two core therapeutic areas; autoimmunity & inflammation and anti-infectives.
*Phase 2/3 adaptive trial becomes a pivotal trial for filing
Our core therapeutic areas
The P140 platform
LUPUZORTM for Lupus
P140 for CIDP
for systemic fungal infections
for severe bacterial infections